AIMS OF THE STUDY: To examine the patterns of use, complication rates, and survival in elderly recipients of implantable cardioverter defibrillators (ICD). METHODS AND RESULTS: We followed 500 consecutive patients included in the Marburg Defibrillator database for 48+/-39 months. There were 40 patients (8%) >/= 75 and 460 (92%) < 75 years of age at the time of implant. The 5-year Kaplan-Meier estimate for appropriate treatment of VT or VF by ICD was 49% among patients < 75- versus 57% among patients >/= 75-years-old (P = 0.17). The 5-year sudden death rate was similarly low in both groups of patients (2% versus 3%). The 5-year overall mortality rate was significantly higher in patients >/= 75 than in patients < 75 years of age (55% versus 21%, P = 0.001), due to a higher mortality from heart failure (HF). All procedure-related, lead-related, and pulse generator-related complications were similar in both patient groups (23% versus 25%). CONCLUSIONS: ICD therapy was equally effective in patients >/= 75 and patients < 75 years of age in the prevention of sudden cardiac death. While the complication rates were similar in both age groups, the long-term mortality was considerably higher in elderly patients, due to a higher mortality from HF. The current ICD therapy guidelines appear applicable to elderly patients who are otherwise medically stable and without advanced HF.
AIMS OF THE STUDY: To examine the patterns of use, complication rates, and survival in elderly recipients of implantable cardioverter defibrillators (ICD). METHODS AND RESULTS: We followed 500 consecutive patients included in the Marburg Defibrillator database for 48+/-39 months. There were 40 patients (8%) >/= 75 and 460 (92%) < 75 years of age at the time of implant. The 5-year Kaplan-Meier estimate for appropriate treatment of VT or VF by ICD was 49% among patients < 75- versus 57% among patients >/= 75-years-old (P = 0.17). The 5-year sudden death rate was similarly low in both groups of patients (2% versus 3%). The 5-year overall mortality rate was significantly higher in patients >/= 75 than in patients < 75 years of age (55% versus 21%, P = 0.001), due to a higher mortality from heart failure (HF). All procedure-related, lead-related, and pulse generator-related complications were similar in both patient groups (23% versus 25%). CONCLUSIONS:ICD therapy was equally effective in patients >/= 75 and patients < 75 years of age in the prevention of sudden cardiac death. While the complication rates were similar in both age groups, the long-term mortality was considerably higher in elderly patients, due to a higher mortality from HF. The current ICD therapy guidelines appear applicable to elderly patients who are otherwise medically stable and without advanced HF.
Authors: Ahmad Yaminisharif; Nader Soofizadeh; Akbar Shafiee; Ali Kazemisaeid; Arash Jalali; Ali Vasheghani-Farahani Journal: Int Cardiovasc Res J Date: 2014-04-01